Weight loss in patients with type 2 diabetes receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: A post-hoc analysis of the AWARD-4 study across baseline body mass index subgroups.

Fuechtenbusch M, Aberle J, Heitmann E, Nicolay C, Jung H

Diabetes, obesity & metabolism15 Mar 2019Cited by 9 (Europe PMC)

PMID30737891DOI10.1111/dom.13658PepBankPUB-30737891

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

13 results from studies that gave the peptide. 13 results from people.

01HumanNon-randomized trialEfficacy outcome
In insulin-treated T2D patients, dulaglutide groups used lower total daily insulin doses than the glargine group.
In plain wordsIn insulin-treated T2D patients, the dulaglutide groups used less daily insulin than the glargine group.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseMean total daily insulin dose
Study
n = 884
Comparator
Insulin glargine with prandial insulin lispro
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg or 0.75 mg once weekly · 52 weeksAs given in this study (human).
Source sentences
Summary
The following parameters were statistically significant (P < 0.01) in favour of the dulaglutide-treated groups, at lower mean total daily insulin doses, vs the insulin glargine group.
2 context sentences(design, population, supporting numbers)
Summary · context
Post-hoc analyses of body weight and insulin dose data from the AWARD-4 trial involved comparison of treatment with once-weekly dulaglutide 1.5 mg (N = 295) or 0.75 mg (N = 293) and treatment with daily insulin glargine (N = 296), each with prandial insulin lispro (± metformin).
Summary · context
Changes in weight and in the proportion of patients without weight gain or with weight loss of at least 3%, 5% or 10% or composites of HbA1c less than 7% without weight gain and weight loss of at least 3% after 52 weeks were compared between the dulaglutide (either dose) groups and the insulin glarg…
Report a problemFND-3073789113
02HumanNon-randomized trialEfficacy outcome
In insulin-treated T2D patients, dulaglutide 1.5 mg with lispro reduced weight more than glargine with lispro.
In plain wordsIn insulin-treated T2D patients, dulaglutide 1.5 mg with lispro reduced weight more than glargine with lispro.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseWeight change
Study
n = 591
Comparator
Insulin glargine with prandial insulin lispro
Outcome group
Body weight · Metabolic and weight
Studied dose
1.5 mg once weekly · 52 weeksAs given in this study (human).
Measurements
LSM weight change difference
−3.23 kg
dulaglutide 1.5 mg versus insulin glargine
Source sentences
Summary
The achieved targets were more pronounced with dulaglutide 1.5 mg than with insulin glargine: LSM weight change difference, -3.23 kg;
3 context sentences(design, population, supporting numbers)
Summary · context
The following parameters were statistically significant (P < 0.01) in favour of the dulaglutide-treated groups, at lower mean total daily insulin doses, vs the insulin glargine group.
Summary · context
Post-hoc analyses of body weight and insulin dose data from the AWARD-4 trial involved comparison of treatment with once-weekly dulaglutide 1.5 mg (N = 295) or 0.75 mg (N = 293) and treatment with daily insulin glargine (N = 296), each with prandial insulin lispro (± metformin).
Summary · context
Changes in weight and in the proportion of patients without weight gain or with weight loss of at least 3%, 5% or 10% or composites of HbA1c less than 7% without weight gain and weight loss of at least 3% after 52 weeks were compared between the dulaglutide (either dose) groups and the insulin glarg…
Report a problemFND-3073789107
03HumanNon-randomized trialEfficacy outcome
In insulin-treated T2D patients, more avoided weight gain with dulaglutide 1.5 mg and lispro than glargine and lispro.
In plain wordsIn insulin-treated T2D patients, more avoided weight gain with dulaglutide 1.5 mg and lispro than glargine and lispro.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseNo weight gain
Study
n = 591
Comparator
Insulin glargine with prandial insulin lispro
Outcome group
Body weight · Metabolic and weight
Studied dose
1.5 mg once weekly · 52 weeksAs given in this study (human).
Measurements
No weight gain
49%
dulaglutide 1.5 mg
No weight gain
19%
insulin glargine
Source sentences
Summary
proportion of patients without weight gain, 49.0% vs 19.0%;
3 context sentences(design, population, supporting numbers)
Summary · context
The following parameters were statistically significant (P < 0.01) in favour of the dulaglutide-treated groups, at lower mean total daily insulin doses, vs the insulin glargine group.
Summary · context
Post-hoc analyses of body weight and insulin dose data from the AWARD-4 trial involved comparison of treatment with once-weekly dulaglutide 1.5 mg (N = 295) or 0.75 mg (N = 293) and treatment with daily insulin glargine (N = 296), each with prandial insulin lispro (± metformin).
Summary · context
Changes in weight and in the proportion of patients without weight gain or with weight loss of at least 3%, 5% or 10% or composites of HbA1c less than 7% without weight gain and weight loss of at least 3% after 52 weeks were compared between the dulaglutide (either dose) groups and the insulin glarg…
Report a problemFND-3073789108
04HumanNon-randomized trialEfficacy outcome
In insulin-treated T2D patients, more lost ≥3% weight with dulaglutide 1.5 mg and lispro than glargine and lispro.
In plain wordsIn insulin-treated T2D patients, more lost ≥3% weight with dulaglutide 1.5 mg and lispro than glargine and lispro.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseWeight loss at least 3%
Study
n = 591
Comparator
Insulin glargine with prandial insulin lispro
Outcome group
Body weight · Metabolic and weight
Studied dose
1.5 mg once weekly · 52 weeksAs given in this study (human).
Measurements
Weight loss ≥3%
21.7%
dulaglutide 1.5 mg
Weight loss ≥3%
5.7%
insulin glargine
Source sentences
Summary
proportion of patients with weight loss ≥3%, 21.7% vs 5.7%
3 context sentences(design, population, supporting numbers)
Summary · context
The following parameters were statistically significant (P < 0.01) in favour of the dulaglutide-treated groups, at lower mean total daily insulin doses, vs the insulin glargine group.
Summary · context
Post-hoc analyses of body weight and insulin dose data from the AWARD-4 trial involved comparison of treatment with once-weekly dulaglutide 1.5 mg (N = 295) or 0.75 mg (N = 293) and treatment with daily insulin glargine (N = 296), each with prandial insulin lispro (± metformin).
Summary · context
Changes in weight and in the proportion of patients without weight gain or with weight loss of at least 3%, 5% or 10% or composites of HbA1c less than 7% without weight gain and weight loss of at least 3% after 52 weeks were compared between the dulaglutide (either dose) groups and the insulin glarg…
Report a problemFND-3073789109
05HumanNon-randomized trialEfficacy outcome
In insulin-treated T2D patients, more lost ≥5% weight with dulaglutide and lispro than glargine and lispro.
In plain wordsIn insulin-treated T2D patients, more lost ≥5% weight with dulaglutide and lispro than glargine and lispro.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseWeight loss at least 5%
Study
n = 591
Comparator
Insulin glargine with prandial insulin lispro
Outcome group
Body weight · Metabolic and weight
Studied dose
1.5 mg once weekly · 52 weeksAs given in this study (human).
Measurements
Weight loss ≥5%
10.5%
dulaglutide 1.5 mg
Weight loss ≥5%
2.4%
insulin glargine
Source sentences
Summary
or with weight loss ≥5%, 10.5% vs 2.4%;
3 context sentences(design, population, supporting numbers)
Summary · context
The following parameters were statistically significant (P < 0.01) in favour of the dulaglutide-treated groups, at lower mean total daily insulin doses, vs the insulin glargine group.
Summary · context
Post-hoc analyses of body weight and insulin dose data from the AWARD-4 trial involved comparison of treatment with once-weekly dulaglutide 1.5 mg (N = 295) or 0.75 mg (N = 293) and treatment with daily insulin glargine (N = 296), each with prandial insulin lispro (± metformin).
Summary · context
Changes in weight and in the proportion of patients without weight gain or with weight loss of at least 3%, 5% or 10% or composites of HbA1c less than 7% without weight gain and weight loss of at least 3% after 52 weeks were compared between the dulaglutide (either dose) groups and the insulin glarg…
Report a problemFND-3073789110
06HumanNon-randomized trialEfficacy outcome
In insulin-treated T2D patients, more reached HbA1c <7% without weight gain with dulaglutide and lispro than glargine and lispro.
In plain wordsIn insulin-treated T2D patients, more reached HbA1c <7% without weight gain with dulaglutide and lispro than glargine and lispro.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseHbA1c below 7% without weight gain
Study
n = 591
Comparator
Insulin glargine with prandial insulin lispro
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg once weekly · 52 weeksAs given in this study (human).
Measurements
Composite response
26.2%
dulaglutide 1.5 mg
Composite response
7.9%
insulin glargine
Source sentences
Summary
proportion of patients with HbA1c <7% without weight gain, 26.2% vs 7.9%;
3 context sentences(design, population, supporting numbers)
Summary · context
The following parameters were statistically significant (P < 0.01) in favour of the dulaglutide-treated groups, at lower mean total daily insulin doses, vs the insulin glargine group.
Summary · context
Post-hoc analyses of body weight and insulin dose data from the AWARD-4 trial involved comparison of treatment with once-weekly dulaglutide 1.5 mg (N = 295) or 0.75 mg (N = 293) and treatment with daily insulin glargine (N = 296), each with prandial insulin lispro (± metformin).
Summary · context
Changes in weight and in the proportion of patients without weight gain or with weight loss of at least 3%, 5% or 10% or composites of HbA1c less than 7% without weight gain and weight loss of at least 3% after 52 weeks were compared between the dulaglutide (either dose) groups and the insulin glarg…
Report a problemFND-3073789111
07HumanNon-randomized trialEfficacy outcome
In insulin-treated T2D patients, more reached HbA1c <7% with ≥3% weight loss with dulaglutide and lispro than glargine and lispro.
In plain wordsIn insulin-treated T2D patients, more reached HbA1c <7% with ≥3% weight loss with dulaglutide and lispro than glargine and lispro.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseHbA1c below 7% and weight loss at least 3%
Study
n = 591
Comparator
Insulin glargine with prandial insulin lispro
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg once weekly · 52 weeksAs given in this study (human).
Measurements
Composite response
11.9%
dulaglutide 1.5 mg
Composite response
1.4%
insulin glargine
Source sentences
Summary
proportion of patients with HbA1c <7% and weight loss ≥3%, 11.9% vs 1.4%, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
The following parameters were statistically significant (P < 0.01) in favour of the dulaglutide-treated groups, at lower mean total daily insulin doses, vs the insulin glargine group.
Summary · context
Post-hoc analyses of body weight and insulin dose data from the AWARD-4 trial involved comparison of treatment with once-weekly dulaglutide 1.5 mg (N = 295) or 0.75 mg (N = 293) and treatment with daily insulin glargine (N = 296), each with prandial insulin lispro (± metformin).
Summary · context
Changes in weight and in the proportion of patients without weight gain or with weight loss of at least 3%, 5% or 10% or composites of HbA1c less than 7% without weight gain and weight loss of at least 3% after 52 weeks were compared between the dulaglutide (either dose) groups and the insulin glarg…
Report a problemFND-3073789112
08HumanNon-randomized trialEfficacy outcome
In insulin-treated T2D patients, weight change favored dulaglutide 0.75 mg with lispro over glargine with lispro.
In plain wordsIn insulin-treated T2D patients, weight change favored dulaglutide 0.75 mg with lispro over glargine with lispro.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseWeight change
Study
n = 589
Comparator
Insulin glargine with prandial insulin lispro
Outcome group
Body weight · Metabolic and weight
Studied dose
0.75 mg once weekly · 52 weeksAs given in this study (human).
Source sentences
Summary
The following parameters were statistically significant (P < 0.01) in favour of the dulaglutide-treated groups, at lower mean total daily insulin doses, vs the insulin glargine group.
3 context sentences(design, population, supporting numbers)
Summary · context
The achieved targets were more pronounced with dulaglutide 1.5 mg than with insulin glargine: LSM weight change difference, -3.23 kg;
Summary · context
Post-hoc analyses of body weight and insulin dose data from the AWARD-4 trial involved comparison of treatment with once-weekly dulaglutide 1.5 mg (N = 295) or 0.75 mg (N = 293) and treatment with daily insulin glargine (N = 296), each with prandial insulin lispro (± metformin).
Summary · context
Changes in weight and in the proportion of patients without weight gain or with weight loss of at least 3%, 5% or 10% or composites of HbA1c less than 7% without weight gain and weight loss of at least 3% after 52 weeks were compared between the dulaglutide (either dose) groups and the insulin glarg…
Report a problemFND-3073789101
09HumanNon-randomized trialEfficacy outcome
In insulin-treated T2D patients, avoidance of weight gain favored dulaglutide 0.75 mg with lispro over glargine with lispro.
In plain wordsIn insulin-treated T2D patients, avoidance of weight gain favored dulaglutide 0.75 mg with lispro over glargine with lispro.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseNo weight gain
Study
n = 589
Comparator
Insulin glargine with prandial insulin lispro
Outcome group
Body weight · Metabolic and weight
Studied dose
0.75 mg once weekly · 52 weeksAs given in this study (human).
Source sentences
Summary
The following parameters were statistically significant (P < 0.01) in favour of the dulaglutide-treated groups, at lower mean total daily insulin doses, vs the insulin glargine group.
3 context sentences(design, population, supporting numbers)
Summary · context
proportion of patients without weight gain, 49.0% vs 19.0%;
Summary · context
Post-hoc analyses of body weight and insulin dose data from the AWARD-4 trial involved comparison of treatment with once-weekly dulaglutide 1.5 mg (N = 295) or 0.75 mg (N = 293) and treatment with daily insulin glargine (N = 296), each with prandial insulin lispro (± metformin).
Summary · context
Changes in weight and in the proportion of patients without weight gain or with weight loss of at least 3%, 5% or 10% or composites of HbA1c less than 7% without weight gain and weight loss of at least 3% after 52 weeks were compared between the dulaglutide (either dose) groups and the insulin glarg…
Report a problemFND-3073789102
10HumanNon-randomized trialEfficacy outcome
In insulin-treated T2D patients, ≥3% weight loss attainment favored dulaglutide 0.75 mg with lispro over glargine with lispro.
In plain wordsIn insulin-treated T2D patients, ≥3% weight loss attainment favored dulaglutide 0.75 mg with lispro over glargine with lispro.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseWeight loss at least 3%
Study
n = 589
Comparator
Insulin glargine with prandial insulin lispro
Outcome group
Body weight · Metabolic and weight
Studied dose
0.75 mg once weekly · 52 weeksAs given in this study (human).
Source sentences
Summary
The following parameters were statistically significant (P < 0.01) in favour of the dulaglutide-treated groups, at lower mean total daily insulin doses, vs the insulin glargine group.
3 context sentences(design, population, supporting numbers)
Summary · context
proportion of patients with weight loss ≥3%, 21.7% vs 5.7%
Summary · context
Post-hoc analyses of body weight and insulin dose data from the AWARD-4 trial involved comparison of treatment with once-weekly dulaglutide 1.5 mg (N = 295) or 0.75 mg (N = 293) and treatment with daily insulin glargine (N = 296), each with prandial insulin lispro (± metformin).
Summary · context
Changes in weight and in the proportion of patients without weight gain or with weight loss of at least 3%, 5% or 10% or composites of HbA1c less than 7% without weight gain and weight loss of at least 3% after 52 weeks were compared between the dulaglutide (either dose) groups and the insulin glarg…
Report a problemFND-3073789103
11HumanNon-randomized trialEfficacy outcome
In insulin-treated T2D patients, ≥5% weight loss attainment favored dulaglutide 0.75 mg with lispro over glargine with lispro.
In plain wordsIn insulin-treated T2D patients, ≥5% weight loss attainment favored dulaglutide 0.75 mg with lispro over glargine with lispro.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseWeight loss at least 5%
Study
n = 589
Comparator
Insulin glargine with prandial insulin lispro
Outcome group
Body weight · Metabolic and weight
Studied dose
0.75 mg once weekly · 52 weeksAs given in this study (human).
Source sentences
Summary
The following parameters were statistically significant (P < 0.01) in favour of the dulaglutide-treated groups, at lower mean total daily insulin doses, vs the insulin glargine group.
3 context sentences(design, population, supporting numbers)
Summary · context
or with weight loss ≥5%, 10.5% vs 2.4%;
Summary · context
Post-hoc analyses of body weight and insulin dose data from the AWARD-4 trial involved comparison of treatment with once-weekly dulaglutide 1.5 mg (N = 295) or 0.75 mg (N = 293) and treatment with daily insulin glargine (N = 296), each with prandial insulin lispro (± metformin).
Summary · context
Changes in weight and in the proportion of patients without weight gain or with weight loss of at least 3%, 5% or 10% or composites of HbA1c less than 7% without weight gain and weight loss of at least 3% after 52 weeks were compared between the dulaglutide (either dose) groups and the insulin glarg…
Report a problemFND-3073789104
12HumanNon-randomized trialEfficacy outcome
In insulin-treated T2D patients, HbA1c <7% without weight gain favored dulaglutide 0.75 mg with lispro over glargine with lispro.
In plain wordsIn insulin-treated T2D patients, HbA1c <7% without weight gain favored dulaglutide 0.75 mg with lispro over glargine with lispro.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseHbA1c below 7% without weight gain
Study
n = 589
Comparator
Insulin glargine with prandial insulin lispro
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg once weekly · 52 weeksAs given in this study (human).
Source sentences
Summary
The following parameters were statistically significant (P < 0.01) in favour of the dulaglutide-treated groups, at lower mean total daily insulin doses, vs the insulin glargine group.
3 context sentences(design, population, supporting numbers)
Summary · context
proportion of patients with HbA1c <7% without weight gain, 26.2% vs 7.9%;
Summary · context
Post-hoc analyses of body weight and insulin dose data from the AWARD-4 trial involved comparison of treatment with once-weekly dulaglutide 1.5 mg (N = 295) or 0.75 mg (N = 293) and treatment with daily insulin glargine (N = 296), each with prandial insulin lispro (± metformin).
Summary · context
Changes in weight and in the proportion of patients without weight gain or with weight loss of at least 3%, 5% or 10% or composites of HbA1c less than 7% without weight gain and weight loss of at least 3% after 52 weeks were compared between the dulaglutide (either dose) groups and the insulin glarg…
Report a problemFND-3073789105
13HumanNon-randomized trialEfficacy outcome
In insulin-treated T2D patients, combined HbA1c and weight target attainment favored dulaglutide 0.75 mg with lispro over glargine with lispro.
In plain wordsIn insulin-treated T2D patients, combined HbA1c and weight targets favored dulaglutide 0.75 mg with lispro over glargine with lispro.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseHbA1c below 7% and weight loss at least 3%
Study
n = 589
Comparator
Insulin glargine with prandial insulin lispro
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg once weekly · 52 weeksAs given in this study (human).
Source sentences
Summary
The following parameters were statistically significant (P < 0.01) in favour of the dulaglutide-treated groups, at lower mean total daily insulin doses, vs the insulin glargine group.
3 context sentences(design, population, supporting numbers)
Summary · context
proportion of patients with HbA1c <7% and weight loss ≥3%, 11.9% vs 1.4%, respectively.
Summary · context
Post-hoc analyses of body weight and insulin dose data from the AWARD-4 trial involved comparison of treatment with once-weekly dulaglutide 1.5 mg (N = 295) or 0.75 mg (N = 293) and treatment with daily insulin glargine (N = 296), each with prandial insulin lispro (± metformin).
Summary · context
Changes in weight and in the proportion of patients without weight gain or with weight loss of at least 3%, 5% or 10% or composites of HbA1c less than 7% without weight gain and weight loss of at least 3% after 52 weeks were compared between the dulaglutide (either dose) groups and the insulin glarg…
Report a problemFND-3073789106

Studies that did not test the peptide alone1

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

14HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In insulin-treated T2D patients, dulaglutide-versus-glargine effects on the reported weight and composite targets did not differ significantly across BMI categories.
In plain wordsIn insulin-treated T2D patients, dulaglutide-versus-glargine effects on weight and combined targets did not differ significantly across BMI groups.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeTreatment effect variation by BMI
Study
n = 884
Comparator
Insulin glargine with prandial insulin lispro
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Treatment effect for these parameters was not significantly different across BMI categories.
2 context sentences(design, population, supporting numbers)
Summary · context
Post-hoc analyses of body weight and insulin dose data from the AWARD-4 trial involved comparison of treatment with once-weekly dulaglutide 1.5 mg (N = 295) or 0.75 mg (N = 293) and treatment with daily insulin glargine (N = 296), each with prandial insulin lispro (± metformin).
Summary · context
Changes in weight and in the proportion of patients without weight gain or with weight loss of at least 3%, 5% or 10% or composites of HbA1c less than 7% without weight gain and weight loss of at least 3% after 52 weeks were compared between the dulaglutide (either dose) groups and the insulin glarg…
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3073789114

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.